-
公开(公告)号：US06353089B1
公开(公告)日：2002-03-05
申请号：US09348797
申请日：1999-07-07
IPC分类号： C07K706
CPC分类号： C07K16/30 , A61K38/00 , C07K14/4748 , Y10S530/828
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These “T-RAS” bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
摘要翻译： 已经鉴定了源于肿瘤排斥前体MAGE-3的肿瘤排斥抗原。 这些“T-RAS”与MHC-I类分子HLA-A2结合，并且所得复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。 肽和复合物可以用于诊断，治疗和用作产生抗体的免疫原，或用作产生溶细胞T细胞克隆的靶标。
-
公开(公告)号：US5554506A
公开(公告)日：1996-09-10
申请号：US217187
申请日：1994-03-24
IPC分类号： G01N33/53 , A61K35/26 , A61K38/00 , A61K39/395 , A61P35/00 , C07K7/06 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/44 , C12N5/06 , C12P21/08 , G01N33/577 , G01N33/567 , C07K7/00 , G01N33/574
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , Y10S530/828
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
-
3.发明授权Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof 失效与HLA-A2分子复合的分离的MAGE-3衍生的肽及其用途
公开(公告)号：US6019987A
公开(公告)日：2000-02-01
申请号：US668560
申请日：1996-06-21
IPC分类号： G01N33/53 , A61K35/26 , A61K38/00 , A61K39/395 , A61P35/00 , C07K7/06 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/44 , C12N5/06 , C12P21/08 , G01N33/577 , A61K39/00 , C07K16/00 , C12N15/85
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , Y10S530/828
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
摘要翻译： 已经鉴定了源于肿瘤排斥前体MAGE-3的肿瘤排斥抗原。 这些“TRAS”与MHC-I类分子HLA-A2结合，并且所得复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。 肽和复合物可以用于诊断，治疗和用作产生抗体的免疫原，或用作产生溶细胞T细胞克隆的靶标。
-
4.发明授权Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules 失效使用MAGE相关肽的结合物和肽和HLA分子的复合物筛选癌症的方法公开(公告)号：US06379901B1
公开(公告)日：2002-04-30
申请号：US08443580
申请日：1995-05-17
申请人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurguin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
发明人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurguin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
IPC分类号： G01N3353
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , C07K16/30
摘要： The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及衍生自由MAGE-3基因编码的肿瘤排斥抗原前体的非肽。 这种非肽由HLA分子HLA-A1呈递。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
公开(公告)号：US06222012B1
公开(公告)日：2001-04-24
申请号：US08393273
申请日：1995-02-23
申请人： Thierry Boon-Falleur , Pierre Van der Bruggen , Etienne De Plaen , Christoph Lurquin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde , Pedro Romero
发明人： Thierry Boon-Falleur , Pierre Van der Bruggen , Etienne De Plaen , Christoph Lurquin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde , Pedro Romero
IPC分类号： C07K700
CPC分类号： C07K16/30 , A61K38/00 , A61K39/00 , C07K14/4748
摘要： The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及由HLA分子如HLA-A1结合的非肽。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
6.发明授权Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules 失效对MAGE相关肽和HLA分子的复合物分离的分离的溶细胞T细胞
公开(公告)号：US5695994A
公开(公告)日：1997-12-09
申请号：US443341
申请日：1995-05-17
申请人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurguin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
发明人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurguin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
IPC分类号： G01N33/53 , A61K35/16 , A61K38/00 , A61K39/00 , A61K39/395 , A61P37/00 , C07K1/00 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C07K17/00 , C12N5/10 , C12N15/09 , C12N15/11 , C12P21/02 , C12P21/08 , G01N33/574 , G01N33/577 , C12N5/06 , C12N5/08
CPC分类号： C07K14/4748 , C07K16/30 , A61K38/00 , A61K39/00
摘要： The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及衍生自由MAGE-3基因编码的肿瘤排斥抗原前体的非肽。 这种非肽由HLA分子HLA-A1呈递。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
7.发明授权
公开(公告)号：US5462871A
公开(公告)日：1995-10-31
申请号：US073103
申请日：1993-06-07
申请人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
发明人： Thierry Boon-Falleur , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari , Beatrice Gaugler , Benoit Van den Eynde
IPC分类号： G01N33/53 , A61K38/00 , A61K39/00 , A61K39/395 , A61P37/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C12N5/10 , C12N5/12 , C12N5/18 , C12N15/09 , C12P21/02 , C12P21/08 , G01N33/574 , G01N33/577 , C12N15/12 , C12N1/21
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , A61K39/00
摘要： The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.
摘要翻译： 本发明涉及编码衍生自MAGE肿瘤排斥抗原前体的非肽的分离的核酸分子。 非肽与细胞表面呈现的人白细胞抗原形成复合物，并导致细胞溶解性T淋巴细胞裂解这些细胞。 因此，它们在诊断方法中是有用的。 本发明的一部分也是设计用于编码已经用本发明的分离的核酸分子转化或转染的非肽以及包含这些分子的载体的细胞系的载体。
-
8.再颁专利Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor 失效编码MAGE-1肿瘤排斥抗原前体的核酸分子公开(公告)号：USRE40089E1
公开(公告)日：2008-02-19
申请号：US08590097
申请日：1996-01-24
申请人： Thierry Boon-Falleur , Pierre Van der Bruggen , Benoit Van den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon-Falleur , Pierre Van der Bruggen , Benoit Van den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , C07K16/30
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译： 本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。 还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。
-
公开(公告)号：US08951747B2
公开(公告)日：2015-02-10
申请号：US13429873
申请日：2012-03-26
IPC分类号： G01N33/00 , C12N5/00 , C12N5/07 , A61K31/7016 , A61K31/4745 , A61K45/06 , C07K14/725 , C07K14/705 , G01N33/50 , C12N5/0783 , C07K16/28 , A61K39/00
CPC分类号： A61K31/7016 , A61K31/4745 , A61K45/06 , A61K2039/5158 , C07K14/7051 , C07K14/70517 , C12N5/0636 , C12N2500/22 , C12N2500/34 , C12N2501/59 , C12N2501/73 , G01N33/505 , A61K2300/00
摘要： The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.
摘要翻译： 本发明涉及调节T淋巴细胞活性的方法和组合物。 已经发现，两种T淋巴细胞受体，特别是TCR和CD8在T淋巴细胞表面上彼此间隔一定距离。 通过使用改变这些受体之间距离的调节剂，调节T淋巴细胞的活性。
-
10.发明授权Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules 有权衍生自与HLA-A2分子复合的法师肿瘤排斥抗原前体的分离的肽公开(公告)号：US06682731B1
公开(公告)日：2004-01-27
申请号：US09533499
申请日：2000-03-23
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
IPC分类号： A61K4500
CPC分类号： C07K14/705 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K14/4748
摘要： Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
摘要翻译： 可以使用SEQ ID NO：12和HLA-A2的复合物来产生CTL。 可补充IL-6和IL-12。
-
-
-
-
-
-
-
-
-
搜索结果
161 条记录 (耗时 0.029 秒)
